Current Report Filing (8-k)
14 November 2017 - 7:23AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 13
th
, 2017
CANNABICS PHARMACEUTICALS INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
333-192759
|
20-3373669
|
(State of incorporation)
|
(Commission File Number)
|
(IRS Employer No.)
|
#3 Bethesda Metro Center
Suite 700
Bethesda, Md 20814
(Address of principal executive offices
and Zip Code)
877 424-2429
(Registrant's telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a -12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
o
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item 4.01
|
|
Changes in Registrant's Certifying Accountant
|
Cannabics Pharmaceuticals Inc. (the
“Company”) has replaced Weinberg & Baer LLC (the “Former Accounting Firm”) as its independent registered
public accounting firm, effective as of November 12
th
, 2017, and has engaged Weinstein & Co-; 17 Kissufim St, Jerusalem,
Israel (the “New Accounting Firm”) as its new independent registered public accounting firm as of and for the year
ended August 31
st
, 2017. As described in Item 4.01(a) below, the change in independent registered public
accounting firm is not the result of any disagreement with the Former Accounting Firm. The Board made the decision to engage the
New Accounting Firm acting under authority delegated to it and the Board of Directors approved the same on November 12
th
,
2017.
The Company has not consulted with the
New Accounting Firm during our two most recent fiscal years or during any subsequent interim period prior to its appointment as
New Accounting Firm regarding either (i) the application of accounting principles to a specified transaction, either completed
or proposed; or the type of audit opinion that might be rendered on our financial statements, and neither a written report was
provided to us nor oral advice was provided that the New Accounting Firm concluded was an important factor considered by the Company
in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject
of disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (within
the meaning of Item 304(a)(1)(v) of Regulation S-K).
The Company has requested that the
Former Accounting Firm furnish it with a letter addressed to the Securities and Exchange Commission stating whether or not it agrees
with the above statement. A copy of the letter from the Former Accounting Firm is attached hereto as Exhibit 16.1 to this Form
8-K
16.1
Letter from Weinberg & Baer LLC
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 13
th
, 2017
|
Cannabics Pharmaceuticals Inc.
|
|
|
|
|
|
|
/s/ Itamar Borochov
|
|
By:
|
Itamar Borochov, Director, CEO
|
CNBX Pharmaceuticals (QB) (USOTC:CNBX)
Historical Stock Chart
From Apr 2024 to May 2024
CNBX Pharmaceuticals (QB) (USOTC:CNBX)
Historical Stock Chart
From May 2023 to May 2024